A novel influenza virus neuraminidase inhibitor AV5027

Antiviral Research

Volumn 100, Issue 3, 2013, Pages 698-708

  Ivachtchenko, Alexandre V ^a,b   Ivanenkov, Yan A ^b,c,d   Mitkin, Oleg D ^b   Yamanushkin, Pavel M ^b   Bichko, Vadim V ^d   Leneva, Irina A ^e   Borisova, Olga V ^e  

^a ASAVI LLC   (United States)

^b Chemical Diversity Research Institute   (Russian Federation)

^c MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

^d CHEMDIV INC   (United States)

^e MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

Author keywords

Antiviral; Influenza; Library; Neuraminidase inhibitors

Indexed keywords

ANTIVIRUS AGENT; AV 5027; OSELTAMIVIR; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; 4 (2,2 DIFLUOROACETYLAMINO) 5 AMINO 3 (1 ETHYLPROPOXY)CYCLOHEX 1 ENECARBOXYLIC ACID; 4-(2,2-DIFLUOROACETYLAMINO)-5-AMINO-3-(1-ETHYLPROPOXY)CYCLOHEX-1-ENECARBOXYLIC ACID; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; FLUOROACETIC ACID; NA PROTEIN, INFLUENZA A VIRUS; NA PROTEIN, INFLUENZA B VIRUS; VIRUS PROTEIN;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; CONTROLLED STUDY; MOLECULAR DOCKING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DOG; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MDCK CELL; SYNTHESIS;

ORTHOMYXOVIRIDAE;

ANIMALS; ANTIVIRAL AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLOHEXANECARBOXYLIC ACIDS; DOGS; DRUG DESIGN; FLUOROACETATES; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MADIN DARBY CANINE KIDNEY CELLS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; NEURAMINIDASE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS;

EID: 84887396788     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.10.008     Document Type: Article

References (40)

1. R.B. Belshe, H.M. Smith, C.B. Hall, R. Betts, and A.J. Hay Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection J. Virol. 62 1988 1508 1512
2. K.C. Chou Some remarks on protein attribute prediction and pseudo amino acid composition (50th anniversary year review) J. Theor. Biol. 273 2011 236 247
3. K.C. Chou, and C.T. Zhang Review: prediction of protein structural classes Crit. Rev. Biochem. Mol. Biol. 30 1995 275 349
4. Q.S. Du, S.Q. Wang, and K.C. Chou Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus Biochem. Biophys. Res. Commun. 362 2007 525 531
5. Q.S. Du, R.B. Huang, S.Q. Wang, and K.C. Chou Designing inhibitors of M2 proton channel against H1N1 swine influenza virus PLoS One 5 2010 e9388
6. Q.S. Du, S.Q. Wang, R.B. Huang, and K.C. Chou Computational 3D structures of drug-targeting proteins in the 2009-H1N1influenza A virus Chem. Phys. Lett. 485 2010 191 195
7. M. Esmaeili, H. Mohabatkar, and S. Mohsenzadeh Using the concept of Chou's pseudo amino acid composition for risk type prediction of human papillomaviruses J. Theor. Biol. 263 2010 203 209
8. D.N. Georgiou, T.E. Karakasidis, J.J. Nieto, and A. Torres Use of fuzzy clustering technique and matrices to classify amino acids and its impact to Chou's pseudo amino acid composition J. Theor. Biol. 257 2009 17 26
9. K. Gong, L. Li, J.F. Wang, F. Cheng, D.Q. Wei, and K.C. Chou Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design Med. Chem. 5 2009 242 249
10. M.R. Griffin Influenza vaccination: a 21st century dilemma S. D. Med. 2013 Spec No: 110-118
11. A.J. Hay, and F.G. Hayden Oseltamivir resistance during treatment of H7N9 infection Lancet 381 2013 2230 2232
12. Hayden, F., 2002. WHO Guidelines on the Use of Vaccines and Antivirals during Influenza - Annex 5-Considerations for the Use of Antivirals during an Influenza pandemic, Geneva, 2-4 October, Available from: < http://whqlibdoc.who.int/hq/2004/WHO-CDS-CSR-RMD-2004.8-eng.pdf>.
13. H.-D. Höltje, W. Sippl, D. Rognan, and G. Folkers Molecular Modeling 2008 Wiley-VCH Weinheim [p. 320, Revised and expanded Edition]
14. R.B. Huang, Q.S. Du, C.H. Wang, and K.C. Chou An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus Biochem. Biophys. Res. Commun. 377 2008 1243 1247
15. A. Hurt Standard Operating Procedure WHO - 025 2009 WHO Collaborating Centre for Reference & Research on Influenza Australia
16. Ivachtchenko, A.V., 2012. RU 2469020.
17. Ivachtchenko, A.V. 2013. WO 2013/070118.
18. C.U. Kim, W. Lew, M.A. Williams, H. Liu, L. Zhang, S. Swaminathan, N. Bischofberger, M.S. Chen, D.B. Mendel, C.Y. Tai, W.G. Laver, and R.C. Stevens Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity J. Am. Chem. Soc. 119 1997 681 690 (Pubitemid 27101232)
19. J.H. Kim, R. Resende, T. Wennekes, H.M. Chen, N. Bance, S. Buchini, A.G. Watts, P. Pilling, V.A. Streltsov, M. Petric, R. Liggins, S. Barrett, J.L. McKimm-Breschkin, M. Niikura, and S.G. Withers Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity Science 340 2013 71 75
20. F. Konno, T. Arai, M.-R. Zhang, A. Hatori, K. Yanamoto, M. Ogawa, G. Ito, C. Odawara, T. Yamasaki, K. Kato, and K. Suzuki Radiosyntheses of two positron emission tomography probes: [11C]Oseltamivir and its active metabolite [11C]Ro 64-0802 Bioorg. Med. Chem. Lett. 18 2008 1260 1263 (Pubitemid 351226552)
21. I.A. Leneva, R.J. Russell, Y.S. Boriskin, and A.J. Hay Characteristics of Arbidol-resistant mutants of Influenza virus: Implications for the mechanism of anti-influenza action of Arbidol Antiviral Res. 81 2009 132 140
22. X.B. Li, S.Q. Wang, W.R. Xu, R.L. Wang, and K.C. Chou Novel inhibitor design for Hemagglutinin against H1N1 influenza virus by core hopping method PLoS One 6 2011 e28111
23. Q. Li, J. Qi, Y. Wu, H. Kiyota, K. Tanaka, Y. Suhara, H. Ohrui, Y. Suzuki, C.J. Vavricka, and G.F. Gao Functional and structural analysis of influenza neuraminidase N3 offers further insight into the mechanisms of oseltamivir-resistance J. Virol. 2013 [Epub ahead of print]
24. A. Meeprasert, W. Khuntawee, K. Kamlungsua, N. Nunthaboot, T. Rungrotmongkol, and S. Hannongbua Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1 J. Mol. Graph. Model. 38 2012 148 154
25. A. Monto Viral susceptibility and the choice of influenza antivirals Clin. Infect. Dis. 47 2008 346 348 (Pubitemid 352009353)
26. M. Morita, T. Sone, K. Yamatsugu, Y. Solitome, S. Matsunaga, M. Kanaia, Y. Watanabe, and M. Shibasaki A method for the synthesis of an oseltamivir PET tracer Bioorg. Med. Chem. Lett. 18 2008 600 602
27. R.M. Pielak, R. Jason, J.R. Schnell, and J.J. Chou Mechanism of drug inhibition and drug resistance of influenza A M2 channel Proc. Natl. Acad. Sci. USA 106 2009 7379 7384
28. J.R. Schnell, and J.J. Chou Structure and mechanism of the M2 proton channel of influenza A virus Nature 451 2008 591 595 (Pubitemid 351186272)
29. R.J. Sugrue, G. Bahadur, M.C. Zambon, M. Hall-Smith, A.R. Douglas, and A.J. Hay Specific structural alteration of the influenza haemagglutinin by amantadine EMBO J. 11 1990 3469 3476
30. C.J. Vavricka, Q. Li, Y. Wu, J. Qi, M. Wang, Y. Liu, F. Gao, J. Liu, E. Feng, J. He, J. Wang, H. Liu, H. Jiang, and G.F. Gao Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition PLoS Pathog. 7 2011 e1002249
31. S.Q. Wang, Q.S. Du, and K.C. Chou Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases Biochem. Biophys. Res. Commun. 354 2007 634 640
32. J.F. Wang, D.Q. Wei, and K.C. Chou Insights from investigating the interactions of adamantane-based drugs with the M2 proton channel from the H1N1 swine virus Biochem. Biophys. Res. Commun. 388 2009 413 417
33. S.Q. Wang, Q.S. Du, R.B. Huang, and K.C. Chou Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus Biochem. Biophys. Res. Commun. 386 2009 432 436
34. S.Q. Wang, X.C. Cheng, W.L. Dong, R.L. Wang, and K.C. Chou Three new powerful Oseltamivir derivatives for inhibiting the neuraminidase of influenza virus Biochem. Biophys. Res. Commun. 401 2010 188 191
35. D.Q. Wei, Q.S. Du, H. Sun, and K.C. Chou Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands Biochem. Biophys. Res. Commun. 344 2006 1048 1055
36. www.chemdiv.com, 2013. The official Internet site of Chemdiv - is a Fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. The company features multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business and logistics operations around the world.
37. http://www.molsoft.com, 2013. The official Internet site of Molsoft LLC, a leading provider of tools, databases and consulting services in the area of structure prediction, structural proteomics, bioinformatics, cheminformatics, molecular visualization and animation, and rational drug design.
38. www.rcsb.org, 2013. RCSB PDB - protein data bank.
39. www.talete.mi.it, 2013. The official Internet site of Talete, an Italian company working in chemometrics, data mining, experimental design, Quantitative Structure-activity Relationships (QSAR), molecular chemometrics, molecular descriptors, experimental design, multicriteria decision making and ranking methods.
40. S.W. Zhang, Y.L. Zhang, H.F. Yang, C.H. Zhao, and Q. Pan Using the concept of Chou's pseudo amino acid composition to predict protein subcellular localization: an approach by incorporating evolutionary information and von Neumann entropies Amino Acids 34 2008 565 572